Substrate reduction therapy with eliglustat in patients with Gaucher disease type 1
Pediatric Hematology/Oncology and Immunopathology · 14.04.2026 · 25 (1) · 213-218
DOI: 10.24287/j.1070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 14.04.2026. Verfasst von M. T. Galimova und 1 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Currently, there are two approaches to treating hereditary enzyme deficiency – Gaucher disease: intravenous infusions of recombinant enzyme – imiglucerase, velaglucerase, or taliglucerase (enzyme replacement therapy), and substrate reduction therapy with eliglustat, the advantage of which is oral administration 1–2 times a day. International phase II/III clinical trials conducted between 2006 and 2016 demonstrated high efficacy and safety of eliglustat for adult patients with Gaucher disease type 1 without severe comorbidities. According to the results of these studies, eliglustat was approved for the treatment of Gaucher disease in the United States and the European Union in 2014. A multicenter study evaluating the efficacy and safety of eliglustat in children with Gaucher disease was initiated in 2018 and completed in December 2025. This literature review summarizes data on the mechanism of action of eliglustat, its dosing characteristics, and its potential use in patients with concomitant organ pathology. In addition, the results of a comparison of changes in Gaucher disease biomarkers during substrate reduction therapy with eliglustat and enzyme replacement therapy are presented.
Zitieren
APA
Galimova, M. T., & Lukina, E. A. (2026). Substrate reduction therapy with eliglustat in patients with Gaucher disease type 1. Pediatric Hematology/Oncology and Immunopathology, 25(1), 213-218. https://doi.org/10.24287/j.1070
Vancouver
Galimova MT, Lukina EA. Substrate reduction therapy with eliglustat in patients with Gaucher disease type 1. Pediatric Hematology/Oncology and Immunopathology. 2026;25(1):213-218. doi:10.24287/j.1070
BibTeX
@article{Galimova2026,
author = {Galimova, M. T. and Lukina, E. A.},
title = {Substrate reduction therapy with eliglustat in patients with Gaucher disease type 1},
journal = {Pediatric Hematology/Oncology and Immunopathology},
year = {2026},
volume = {25},
number = {1},
pages = {213--218},
doi = {10.24287/j.1070}
}
EUVIMED